Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk To Restrict Initial Wegovy Sales In China Amid High Demand
Novo Nordisk A/S (NYSE:NVO) plans to limit initial sales of its obesity treatment Wegovy in China as the Danish drugmaker faces the challenge of balancing demand while ensuring global supply.
丹麥製藥公司諾和諾德（Novo Nordisk A/S）（紐約證券交易所：NVO）計劃在中國限制肥胖症治療藥物Wegovy的初始銷售，因爲該公司面臨着在保證全球供應的同時平衡需求的挑戰。
China's National Health Commission survey revealed over half of its 1.4 billion population is overweight or obese.
中國國家衛健委的一項調查顯示，超過14億人口中有超過一半超重或肥胖。
Also Read: Novo Nordisk's Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows.
還閱讀：研究表明，諾和諾德的老一代減肥藥Saxenda與骨密度下降有關。
Maziar Mike Doustdar, Novo Nordisk's chief of international operations, stated the company aims to launch Wegovy in China soon, prioritizing continuous supply without affecting availability elsewhere.
諾和諾德的國際業務總裁Maziar Mike Doustdar表示，該公司旨在儘快在中國推出Wegovy，優先保證在其他地方的供應不受影響。
China's health authorities recently approved Wegovy, offering a new weight loss option in a market where Novo Nordisk's diabetes drug, Ozempic, has been used off-label to shed weight.
中國衛生部門最近批准了Wegovy，爲這個市場提供了一種新的減肥選擇。諾和諾德的糖尿病藥物Ozempic也曾被非處方使用作爲減肥藥。
As urbanization drives obesity rates, China's market for GLP-1 drugs like Wegovy could reach 40 billion yuan ($5.5 billion) by 2030, Bloomberg notes, citing HSBC analysis.
隨着城市化推動肥胖症率上升，中國GLP-1類藥物如Wegovy的市場規模到2030年可能達到400億元人民幣（55億美元），彭博社援引匯豐銀行的分析報告。
However, Novo Nordisk's patent on semaglutide, Wegovy's active ingredient, expires in 2026, with Hangzhou Jiuyuan Gene Engineering Co. and Livzon Pharmaceutical Group Inc. already seeking to produce generic versions.
然而，Wegovy的活性成分semaglutide的諾和諾德專利將於2026年到期，杭州九元基因工程股份有限公司和立普妥藥業集團股份有限公司已經開始尋求生產仿製版。
Eli Lilly And Co (NYSE:LLY) is also a key competitor, with its obesity drug under review in China. Lilly and Innovent Biologics Inc. are also developing a local weight-loss drug that is expected to launch next year.
禮來公司（Eli Lilly And Co，紐約證券交易所：LLY）也是一家重要的競爭對手，其肥胖症藥物正在中國進行審查。禮來和信達生物（Innovent Biologics Inc.）也正在研發一種本地減肥藥物，預計明年推出。
Bloomberg report adds that Novo Nordisk has struggled to meet global demand for Wegovy and Ozempic, but it continues to manufacture semaglutide in Denmark and North Carolina and is planning final production stages in China.
據彭博社報道，諾和諾德一直難以滿足Wegovy和Ozempic的全球需求，但其仍在丹麥和北卡羅來納州生產semaglutide，並計劃在中國進行最後的生產階段。
A 4 billion yuan factory expansion in Tianjin was announced in March.
3月份宣佈在天津進行40億元人民幣的工廠擴建。
While China's national health insurance covers Ozempic for diabetes, Wegovy is unlikely to receive similar reimbursement.
雖然中國國家醫保覆蓋了Ozempic用於糖尿病的治療，Wegovy不可能得到類似的報銷。
As a result, Wegovy will likely target those able to pay out-of-pocket, allowing Novo Nordisk to set prices independently.
因此，Wegovy可能會針對有能力自己支付的人群，讓諾和諾德獨立定價。
Currently, Ozempic is available on major Chinese platforms like JD.com Inc (NASDAQ:JD) and Alibaba Group Holding Ltd.'s (NYSE:BABA) Tmall.
目前，Ozempic已經在中國主要平台上如京東（JD.com Inc （納斯達克：JD））和阿里巴巴集團控股有限公司（紐約證券交易所：BABA）的天貓（Tmall）上架。
Price Action: NVO shares are down 0.10% at $143.52 at last check Thursday.
截至週四最後檢查，NVO股價下跌0.10％，爲143.52美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本文部分內容使用了Benzinga Neuro的幫助。此內容是通過AI工具部分製作的，並由Benzinga編輯進行了審查和發佈。
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
譯文內容由第三人軟體翻譯。